We have demonstrated safe and effective subretinal readministration of recombinant adeno-associated virus serotype (rAAV) to the contralateral eye in large animals and humans even in the setting of preexisting neutralizing antibodies (NAbs). Readministration of AAV to the same retina may be desirable in order to treat additional areas of the retina not targeted initially or to boost transgene expression levels at a later time point. To better understand the immune and structural consequences of subretinal rAAV readministration to the same eye, we administered bilateral subretinal injections of rAAV2-hRPE65v2 to three unaffected non-human primates (NHPs) and repeated the injections in those same eyes 2 months later. Ophthalmic exams and retinal imaging were performed after the first and second injections. Peripheral blood monocytes, serum, and intraocular fluids were collected at baseline and post-injection time points to characterize the cellular and humoral immune responses. Histopathologic and immunohistochemical studies were carried out on the treated retinas. Ipsilateral readministration of AAV2-hRPE65v2 in NHPs did not threaten the ocular or systemic health through the time span of the study. The repeat injections were immunologically and structurally well tolerated, even in the setting of preexisting serum NAbs. Localized structural abnormalities confined to the outer retina and retinal pigmented epithelium (RPE) after readministration of the treatment do not differ from those observed after single or contralateral administration of an AAV carrying a non-therapeutic transgene in NHPs and were not observed in a patient treated with the nearly identical, FDA-approved, AAV2-hRPE65v2 vector (voretigene neparvovec-rzyl), suggesting NHP-specific abnormalities.
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INTRODUCTION
Inherited retinal dystrophies (IRDs) are a large group of molecularly and clinically heterogeneous conditions caused by mutations in genes expressed in the neural retina and retinal pigmented epithelium (RPE). To date, mutations in over 270 genes have been reported to cause various IRDs ranging in severity from a mild, gradual, late onset of vision loss to blindness soon after birth. [1] [2] [3] Until very recently, there was no available treatment for IRDs. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recently approved AAV2-hRPE65v2 (voretigene neparvovec-rzyl, Luxturna, Spark Therapeutics, Philadelphia, PA, USA) for subretinal delivery as gene augmentation treatment for an early onset, autosomal recessive IRD caused by bi-allelic RPE65 mutations. RPE65 is an isomerohydrolase expressed in the RPE that mediates the conversion of all-trans retinyl ester to 11-cis retinol, a key component of light-absorbing pigments in photoreceptor cells. [4] [5] [6] Mutations in RPE65 disrupt the visual cycle and cause early onset IRD known as Leber's congenital amaurosis (LCA). [7] [8] [9] Voretigene neparvovec-rzyl, the name for the clinical-grade version of AAV2-hRPE65v2, carries the wild-type version of the human RPE65 cDNA driven by a constitutive chicken b-actin with a cytomegalovirus enhancer promoter packaged in recombinant adeno-associated virus serotype 2 (rAAV2). This is delivered to the tissue by subretinal injection. [10] [11] [12] The subretinal injections typically lead to transduction of retinal cells only within the area of the localized transient retinal detachment or "bleb" that result. 13 Thus, visual improvement, although impressive, is limited to the location and extent of the treated region. Ipsilateral readministration of gene therapy agents to the retina could be useful in several situations. A likely scenario would be the need to treat additional areas of the retina not targeted during the initial injection, because the blebs do not predictably track to the region planned for treatment pre-operatively. In other scenarios, fragile regions such as the fovea may have been deliberatively spared over concerns of potential tissue damage and potential central vision loss. In such scenarios, it may be desirable to treat the fovea and/or previously untreated regions at a later time point. Finally, if transgene expression levels were to subside over time after a single injection, readministration could be used as a booster in previously transduced cells. 14, 15 The immune and ocular inflammatory response after the subretinal administration of AAV2-hRPE65 in pre-clinical studies in dogs and non-human primate (NHPs) defined the dose range for safe delivery of the vector to patients. 13, [16] [17] [18] Subretinal delivery of gene therapy agents has proven effective and relatively benign, in large part due to the fact that the retina is an immunologically privileged site. [19] [20] [21] We further demonstrated that subretinal readministration of AAV2-hRPE65v2 to the contralateral eye is well tolerated, does not elicit an inflammatory immune response, and results in the predicted gain in retinal function both in affected dogs and in patients. [22] [23] [24] [25] However, to our knowledge, there are no reports of repeated delivery into an already injected retina. The main concern is that local disruption of physical barriers during the initial intervention may prime the immune system to mount a potentially harmful immune response upon readministration of the vector to the same eye. 26, 27 Therefore, a comprehensive understanding of ocular immunogenicity to AAV vectors upon same eye readministration will be useful in defining the safety and feasibility of this procedure. NHP (macaque) eyes are close in size and have similar anatomical constituents and proportions compared to human eyes, including the existence of a nearly identical macular region. [28] [29] [30] Despite expected immunologic differences between humans and NHPs, the ocular immune response to AAV vector administration in NHPs has proven a good predictor of the human immune response. 24, [31] [32] [33] To determine the humoral and cellular immune response to same eye subretinal readministration, we performed studies using GMP-comparable rAAV2-hRPE65v2 (nearly identical to voretigene neparvovec-rzyl) in healthy NHPs. We carried out serial in vivo multimodal retinal imaging after sequential subretinal administration of the vector to the same eye in order to assess changes over time that might correlate with the systemic and local immunologic profile and histopathologic changes ex vivo.
RESULTS

Effects of Bilateral Same-Eye Subretinal Readministration of AAV2-hRPE65v2 in NHPs
Evaluated were three unaffected NHPs $7 to 8 years old at the start of the study (Table 1) . Two were cynomolgus and one was a rhesus macaque. All animals had been studied previously in a pharmacology study that did not involve the eye, and their geographic origins were unknown. There was a >1 year washout between prior drug delivery and the AAV delivery that took place in the current study. Subretinal injections of AAV2-hRPE65v2 were carried out bilaterally and animals were followed 3.5 months after the initial injections ( Figure 1 ; Table 1 ). As expected based on our previous studies, the retinal detachments had resolved by the first ophthalmoscopy post-injection time point (3 days). 13, 24 There were no cells in the anterior chamber (AC) or vitreous compartments. Pigmentary changes delineating the borders of the detachments ("blebs") were noted. Two months later, a second injection of similar volume and dose of AAV2-hRPE65v2 was delivered subretinally in a region that overlapped either completely or partially or avoided altogether the initial treatment region in order to observe any differing effects between the three scenarios ( Figure 1 ; Table 1 ). Retinal imaging was performed 43 and 65 days from the first and second injection, respectively ( Figure 1 ). Visible "watermarks" demarcating the boundaries of the first bleb and vasculature landmarks served as landmarks for the readministration procedures. Pigmentary changes were present in the regions of injection, with hyperpigmentation at the borders of the injected region and hypopigmentation within the bleb in all eyes (Figure 2A ). The changes are visible by ophthalmoscopy and have been observed as early as 3 days after the subretinal injections (data not shown). Fibrous metaplasia was also noted in the inferior blebs of both eyes of 10C015. The blebs were located at a similar distance relative to the optic nerve in superior and/or inferior retina, although some blebs extended into the central macula ( Figure 1 ). The retina surrounding the blebs appeared normal (Figure 2A ). En face retinal imaging with short wavelength fundus autofluorescence (SW-FAF) serves to monitor the health of the RPE, and indirectly the photoreceptors, by capturing the returning autofluorescence (AF) signal produced by the excitation by blue light of lipofuscin and melano-lipofuscin fluorophores within RPE cells. 34, 35 After the initial injections, SW-FAF clearly delineates the edge of the blebs ( Figure 2B , injection 1). The boundaries of the blebs appear as variably hypo-autofluorescent arcs that can be traced until the peripheral edge was out of reach to imaging. The SW-FAF outside of the bleb boundary showed a normally homogeneous gray background in the midperiphery crossed by the dark contour of the retinal vasculature, as well as the dark hypo-AF foveal center caused by absorption of the blue excitation light by the macular pigment. 36 Within the blebs there are striking changes with darker areas of non-homogeneous hypo-AF, some nearly circular, separated from the linear hypo-autofluorescent edge of the bleb by a band of better appearing, light gray, signal (for example, Figure 2B , injection 1). SW-FAF imaging after vector readministration in the eyes of the animal with the non-overlapping blebs replicated the same pattern observed after the initial administration ( Figure 2B , injection 2). Partial overlap of the injected regions (BF54F) resulted in merging of the two blebs without a locally more severe loss of the autofluorescent signal within the overlapping section, whereas the animal with complete bleb overlap (11D086) showed denser hypo-AF within the bleb after readministration.
Spectral domain optical coherence tomography (SD-OCT) imaging was performed as in vivo microscopy of the retina ( Figure 2C ). Topo-graphic maps of the thickness of the retina within the injected blebs performed after the initial injection are very similar to maps generated after readministration, suggesting no major changes in overall retinal thickness occurred for any of the three scenarios tested (non-overlapping, partially overlapping, and totally overlapping blebs) ( Figure 2C ). Particularly, topography maps straddling the boundary between uninjected and injected retina showed no abrupt transitions in thickness (which would indicate thinning within the bleb), but only a smooth transition to a thinner overall retina (cooler colors), which occurs normally with increasing distance from the fovea (uninjected regions, Figure 2C , injection 1). Closer inspection, however, reveals there were local changes in thickness within the blebs. Animal 10C015 shows an area of mild thickening in superior retina after the initial administration that is less obvious following readministration of the vector inferiorly ( Figure 2C ). This area corresponds to a whitish lesion on fundus photography (Figure 2A ). Animal BF54F shows a band-like area of thickening superior to the nerve that also fades on follow up when the readministered bleb partially overlaps with this region. Animal 11D086, who had totally overlapping blebs following readministration, shows no differences in total retinal thickness topography before versus after readministration. The site of the retinotomy, which was used to reinject the same region, can be still seen as a local area of thinning highlighted in blue inferior to the nerve that turns slightly larger in maps after readministration ( Figure 2C ).
Histologic and Immunohistochemistry Correlates of In Vivo Micron-Scale Retinal Imaging
To gain a better insight of the structural changes, we selected single magnified SD-OCT cross-sections from the readministration (injection 2) and initial administration (injection 1) areas. These regions of interest (ROIs) included uninjected retina, boundary edge of the bleb, and areas that showed evident FAF abnormalities on en face imaging ( Figure 2B ). SD-OCT images were scaled and then aligned using vascular elements so that the images would be comparable in magnification, location, and orientation ( Figure 3A ). Nuclear layers (ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer) can be seen running as parallel hyporreflective bands bracketed by the highly reflective signals from the plexiform layers (OPL, outer plexiform layer; IPL, inner plexiform layer) and the retinal nerve fiber layer (RNFL), respectively ( Figure 3A) . The cross-section of superficial large blood vessels shows a hyperreflective image with posterior shadowing ( Figure 3A , asterisk). Those were used to further align images from the first and second injections. Photoreceptor structures distal to the external limiting membrane (ELM) can be seen in cross-section, most noticeable among them at these pericentral/midperipheral locations were the signals originating from the inner segment ellipsoid band zone (EZ), the interdigitation between the tip of the photoreceptor outer segments (POSs) and the apical RPE (interdigitation zone [IZ], band), and RPE/Bruch's membrane (BrM). All cross-sections used for this analysis were located in near midperipheral supero-nasal and infero-nasal retina. At these locations, the cross-sectional profile is relatively flat, allowing for comparisons of relative thickness values of each of the retinal laminae between locations inside the treated retina versus the surrounding untreated regions; the precise registration of the images from each eye between consecutive experiments was needed to assess for relative changes in thicknesses of each of the retinal sublaminae between the two injections.
Qualitatively, there were no obvious changes in any of the main nuclear, synaptic layers, or the RNFL layers in comparisons between uninjected and injected regions in any of the eyes for any of the two experiments or between the images taken after readministration compared to the same locations on initial administration (Figure 3A) . However, closer inspection of the magnified SD-OCT cross-sections revealed various degrees of outer retinal sublaminae changes in the injected regions in most of the eyes. Changes included attenuation of the IZ and/or EZ band signals accompanied in some areas of disruption of the RPE signal by hyperreflectivities (for example, Figure 3A , animal BF54F). The changes occurred in blebs resulting from both the initial and the readministered injections and were apparently independent of the degree of overlapping of the blebs and of the degree of abnormalities in en face FAF imaging. For example, animal 11D086 with overlapping injections and the most severe abnormalities on SW-and near infrared-FAF (NIR-FAF) imaging showed the least changes on SD-OCT imaging at the locations sampled. Interestingly, re-emergence of the IZ band signal in 10C015 suggests some of the abnormalities may be transient, indicating recovery of the POS anatomy with time ( Figure 2A ). However, the disruption of the RPE band with apical hyperreflectivities may represent RPE depigmentation, hypertrophy, or migration and/or accumulation of subretinal inflammatory or degenerative debris.
At the time of necropsy, there were no abnormalities upon gross inspection in any abdominal or thoracic organs or in the brain. Histologic retinal sections obtained at study termination were chosen to closely match the locations represented in the SD-OCT to help understand the significance of the in vivo observations ( Figure 2B ). The histopathologic picture confirmed preservation of the nuclear layers and changes limited to the POS and the RPE consisting of examples of focal RPE hypertrophy that explain irregular hyperreflectivities superficial to the RPE on SD-OCT ( Figures 3A and 3B , animal BF54F, white arrows). All NHPs showed dislodged or hypertrophic RPEs around the injection sites in at least one of their eyes, likely due to the mechanical nature of the injections. There was also mild focal loss of RPE cells or replacement of RPE cells by fibrinoid scar and a rare choroidal infiltrate (animal 11D86, right eye) that closely resembled the SD-OCT findings of loss of irregular hyperreflectivities superficial to the RPE (Figures 2A and 2B , animal BF54F, white ar-rows). There were examples of loss of RPE cells with replacement of RPE cells by fibrinoid scar and a rare choroidal infiltrate ( Figure S1 , animal 11D86, right eye). On histology, animal 11D086, which had almost completely overlapping injections, displayed shorter, yet reattached, POSs in some areas, but these didn't look disarrayed. Partially overlapping injection sites in BF54F showed areas lacking POSs in both eyes. Animal 10C015 also had areas lacking POSs in each of the non-overlapping blebs, but had longer, "cystic" POSs at the first injection site in the right eye.
Histopathology was graded from mild to severe according the number and distribution of inflammatory cells. Findings in NHPs BF54F and 11D086 were both categorized as generally mild and presented with occasional localized pockets of inflammatory cells in the choroid, but not in the subretinal space, suggesting these infiltrates did not have an impact on the retinas. NHP 10C015 exhibited focal inflammatory infiltrates in the subretinal space and therefore was classified as severe. No inflammation in the vitreous or the AC was observed in any of the animals. Quantitative SD-OCT parameters were used to assess for changes in thickness of the total retina, inner retina, and photoreceptor ONL, as well as for the EZ-to-BM distance, a surrogate measure for POS length ( Figure 3C ). The retinal crosssections were segmented (see Materials and Methods; Figure 1 ) and thickness differences for each of the retinal laminae calculated either as a fraction of the thickness value in uninjected retina or as a fraction of the thickness value at the same location after the first injection. The aim was to facilitate comparisons between animals by avoiding expected regional differences in absolute thicknesses. Values were considered significantly different if they exceeded the inter-visit variability of the estimates (3SD = total, 6%; inner retina, 15%; ONL, 7%; EZ-BM, 18%) in uninjected NHP eyes. 37 There were no significant differences in thickness for total, inner, or ONL for any of the injected retinas compared to the neighboring uninjected retina or between the readministered regions compared to the initial administration, confirming qualitative observations ( Figure 3C ). Differences in total retinal thickness expressed as the fraction of the value measured after the initial injection showed mild thinning, nearly identical in injected (mean difference ± 2SD = À3% ± 6%) and uninjected (À2% ± 6%) regions (i.e., inside versus outside injection blebs) (paired t test, p = 0.74). Similarly, the EZ-BM distance showed non-significant thinning in both injected (À3% ± 13%) and uninjected (À6% ± 8%) (p = 0.63) retinas with the variability for the estimates of the injected retina ( Figure 3C , red bar) driven by POS changes of animal BF54F. Comparisons between locations inside versus outside the injected blebs at the 1 st injection or 2 nd injection time points ( Figure 3C , gray and black bars) were more variable reflecting expected normal topographic differences in thickness rather than real differences. Figure S3 ).
We delivered a subretinal injection of clinical grade voretigene neparvovec-rxyz to a patient with LCA caused by bi-allelic mutations (c.271C > T and c.725+2T > A) in RPE65 and asked whether the FAF and SD-OCT abnormalities detected in NHP would be observed post-treatment in the patient. Of note, the procedure in patients, unlike in NHPs, is performed after a core vitrectomy, to prevent longterm complications, such as tractional retinal detachments. 12 The injection bleb in this patient covered the entire area of photoreceptor preservation on SD-OCT retinal thickness topography maps (Figure 5A) . Given that SW-FAF signal is weak or absent in this condition NIR-FAF was favored for FAF imaging ( Figure 5 ). [38] [39] [40] Before treatment there was a residual central oval island of relatively preserved NIR-FAF signal that corresponded with the detectable RPE and ONL signals on SD-OCT ( Figure 5B ). Repeat retinal imaging a month after the subretinal injections show nearly identical images on NIR-FAF, as well as on SD-OCT compared to baseline.
Defining the Immune Response on Same-Eye Readministration of AAV2-hRPE65v2 in NHPs
Baseline serum NAb titers to AAV2 ranged from negligible to high ( Figure 6A ), likely due to prior wild-type AAV2 exposure, which closely resembles the variation in AAV2 antibody titers observed in human sera. 24, 26, 27 As expected, none of the NHPs had a detectable antibody titer to the RPE65 protein at baseline as measured by ELISA. There were no changes in antibodies to RPE65 protein after the injections (data not shown). After the first bilateral subretinal injections, serum AAV2 NAb titers rose significantly in two of the three NHPs. One of them, BF54F, had a negligible titer at baseline. In the other, 10C015, titers rose from <1:100 to peak close to < 1:1,000, but dropped back down to baseline levels after the second injection. There were no observable changes in the remaining NHP ( Figure 6A ). Baseline NAb concentrations to AAV2 in the ACs averaged between the left and right eyes, were <1:10 in all three NHPs. Upon termination of the study, the AAV2 AC NAb titers had risen to <1:100 in BF54F and 1:1,000 in 11D086. There was no observable change in AAV2 antibody titers in the AC of BF54F ( Figure 6B) .
To assess T cell responses to the AAV2 capsid and RPE65 protein, we measured interferon-g (IFN-g) cytokine secretion using an enzymelinked immunosorbent spot (ELISpot) assay on peripheral blood monocyte cells (PBMCs) collected at baseline prior to each subretinal injection and at 2-week intervals following the second injection ( Figure 1 ). Cells were stimulated with AAV2 empty capsid particles and RPE65 peptide pools. Animal BF54F did not have a T cell response at baseline but developed a T cell response to the AAV2 capsid 4 weeks after the second administration of AAV2-hRPE65v2 ( Figure 7 ). This response decreased by the 6 week post-readministration time point. There was no significant T cell response to any of the RPE65 peptide pools.
DISCUSSION
The extraordinarily successful treatment of cases of childhood blindness (RPE65-associated IRD) by gene augmentation with AAV2- hRPE65 has reenergized the entire gene therapy field with the approval by the FDA of this treatment (voretigene neparvovec-rzyl, Luxturna, Spark Therapeutics, Philadelphia, PA, USA) for use in the clinic in December of 2017. A phase III trial that supported this decision demonstrated robust and early improvements in retinal function in the majority of subjects (93%) after a single, localized, subretinal injection of the therapeutic agent in each eye. Sensitivity to light post-treatment increased on average by about 100-fold, supporting enlarged visual fields that permitted better obstacle avoidance and overall improved quality of life. 11 The trial further confirmed the treatment's safety. Complications included temporarily elevated intraocular pressure, cataracts, retinal tear (10% of participants), macular hole (one eye of one participant), and decreased foveal function (albeit improved extrafoveal light sensitivity, one participant), all of which have been attributed to the intraocular surgical procedure needed for the delivery of the recombinant virus to the subretinal space, including a vitrectomy, the creation of a localized retinal detachment, and then a fluid-air exchange within the vitreous cavity. The phase III trial included bilateral administration since safe and successful treatment of the contralateral eyes of previously treated (uniocularly) RPE65 patients had been demonstrated. [22] [23] [24] Readministration of a gene therapy vector to a previously treated eye or region within a tissue such as the retina, however, is an unavoidable subject that has not been explored experimentally in the retina and which has only been limitedly addressed elsewhere. 41, 42 Scenarios where same eye readministration may be indicated include the treatment of untreated regions to further expand vision, the treatment of regions that may be purposely spared during a staged treatment protocol where the frailty of the degenerated retina is tested in visually non-sensitive areas before extending the treatment to include critical areas for vision, such as the central retina, and as a treatment booster should a decline in efficacy be detected over time.
In the present study we used in vivo multimodal retinal imaging, measures of cellular and humoral immunity, and histopathology to explore the consequences of ipsilateral readministration of rAAV2-hRPE65v2 in NHPs. The uncomplicated treatment in patients leaves minimal visible evidence just a few days or weeks after the injections. In contrast, the administration of rAAV2-hRPE65v2 to NHPs produces pigmentary changes within the blebs visible by fundus exam, which can be used to precisely locate a second subretinal injection in relationship to a previous one. In one animal (two eyes), a readministration of the treatment was at a site distant from the first injection to exclude mechanical (surgery-related) effects on the initially injected retina; in the other two animals, the treatment was delivered so that there was a partial or total overlap between the first and second injections. 13, 43 The experiments demonstrated that ipsilateral readministration to the NHP retina was safe from an immunologic standpoint, even when readministration location coincided nearly exactly with the initially treated retinal area. Repeat injections were well tolerated even though the initial injection had resulted in an increase in systemic and local neutralizing antibodies to the AAV2 capsid in two of the animals. There were no clinical signs of inflammation and the ocular media remained clear even though the animals had not been treated with systemic steroids.
In vivo multimodal retinal imaging allows quantitation of the microscopic structure over large expanses of retina, overcoming potential under-sampling and/or simplifying the sampling process that would be required with histology. 44 Structures in the outer retina, such as the POS, as well as potential changes in the content of certain fluorophores within the RPE, such as lipofuscin and melanin, can be readily assessed in vivo, details that can only be viewed with histology after laborious tissue processing. SD-OCT after the initial administration or readministration of rAAV2-hRPE65v2 revealed no obvious signs of intraocular inflammation such as hyperreflective images within the vitreous or the retina that would suggest migration of inflammatory cells or the presence of overt infiltrates. There were, however, examples of subretinal images that may correspond to accumulation of subretinal material, including inflammatory cells, migrated RPE cells and/or shed unphagocytized outer segments. The most consistent and dramatic change on imaging was the presence of round areas of hypo-AF (on SW-and NIR-FAF imaging) within the blebs that corresponded with loss of the IZ signal suggesting POS abnormalities or loss and demelanization of the RPE. 45 Readministration of the vector in the overlapping blebs led to overlapping additional depigmentation but did not lead to worsening of the existing changes. The photoreceptor nuclear layer and the inner retina had a normal appearance, confirming that the abnormalities were compartmentalized to the subretinal space exposed to the treatment. Regions of RPE loss were negative for RPE65 protein by immunohistochemistry suggestive of RPE loss or damage, although neighboring regions with intact RPE showed robust presence of RPE65. Abnormalities of this magnitude have not been reported in humans after subretinal gene therapy for RPE65 deficiency, although versions of this appearance are known to occur after persistent submacular retinal detachments. 14, 46 Similarly, a patient treated with voretigene neparvovec-rzyl and imaged in this study did not show demelanization or loss of the POS. Thus, the abnormalities after subretinal injection of this particular reagent/dose appear to be NHP-specific.
Histopathology of the ipsilateral readministered injections at the termination of the study showed a pattern indistinguishable from earlier descriptions following a one-time subretinal administration of gene therapy products in NHPs. 18, 31, [47] [48] [49] Histopathologic changes included RPE hyperplasia, focal RPE loss, and proliferation. Of note, the immunologic profile was not predictive of the histological abnormalities and did not relate to the overlap between the initial and readministered treatment. For example, the most severe inflammation was observed in the retinas of the animal in which the blebs did not overlap (10C015). Specifically, there were dislodged RPE cells, which were hypertrophic and showed signs of RPE proliferation. In some areas, the border between the RPE and the underlying BM was blurred, which corresponded with retinal imaging findings suggestive of RPE loss and proliferation discussed before. At baseline, this animal did not show evidence of cell-mediated immune response to AAV2, although it did have baseline humoral anti-AAV2 NAbs (reciprocal dilution of >1:10). The inflammation was localized to small focal regions in the choroid underlying the original bleb sites and did not spill into the overlying retina, suggesting a compartmentalized response. There was no evidence of cellular infiltrate that might have been directed at the recombinant AAV or the RPE65 transgene product, except for within isolated pockets in the choroid despite prior exposure to AAV2 based on baseline serum titers. On the other hand, the animal with total overlap between the second and first injection showed the least structural change, whereas the animal with the highest baseline NAb titer directed against AAV2 (11D086) showed the mildest histologic changes after readministration (mild RPE pigment migration and focal RPE disorganization, one mild focal site of choroidal inflammation). Only one animal that had baseline NAb titers to AAV2 (BF54F) developed cell-mediated immune responses to AAV2 4 weeks after the second administration-around the time when an immune response would be expected to be close to maximal-and again the structural change after readministration was indistinguishable from the other two animals.
Dose-dependent outer retinal changes with demelanization of the RPE have been reported after the administration of different vector constructs in NHPs, as well as after injection of control balance salt solutions. 37, 43, 47, 48 These vector-independent abnormalities may be the consequence of low grade, immune-mediated responses within the subretinal space triggered by exposure of foreign proteins that may not be detected by the immune assays used in this work or by routine histopathology. The pigmentary changes post-administration in NHPs noted on fundus examination as early as 72 h post-treatment raise the alternative possibility of acute damage to a particularly susceptible NHP POS and/or RPE to the separation between the layers caused by the subretinal injection. 43, 47 The circular, ring-like autofluorescent patterns documented in these NHP experiments may represent steps of bleb formation or reabsorption that may not occur in humans (for example, Figure 4 , animal 11D086; Reichel et al. 48 ). Such steps may be expected if greater hydraulic forces are required in NHPs compared to humans to overcome the adhesion between the retina and the RPE, which in turn may result in uneven rates of delivery of the subretinal injections. 47, [50] [51] [52] [53] In fact, efforts are underway to de-risk the subretinal injections in patients with the use of mechanical devices that deliver precise volumes at prescribed hydrostatic pressures, as well as with the use of intraoperative SD-OCT systems that allow real time view of the microscopic retinal structure during the surgical interventions. 52, 54 Experiments in NHPs following similar precautions are needed to narrow down the possible causes. 43 The findings are relevant for the interpretation of experiments where foreign proteins are delivered by gene therapy in NHP retinas in preclinical assays of safety, as well as for gene therapy treatments that are being conducted in patients. Although the exact mechanism(s) that lead to these abnormalities are yet to be fully elucidated, limited POS and RPE changes may be expected in similar experiments and may not necessarily indicate an unsafe treatment for patients. 37, 43, [47] [48] [49] 55, 56 Monitoring the health of the injected retina in patients is thus warranted particularly when the target outcome of the retinal gene therapy procedure lies distant to the treated regions, such as in applications where gene therapy is used to produce secretable proteins, because damage or loss of transfected retinal tissue may lead to the loss of the gene product and treatment efficacy. 37, 57 On the other hand, comparatively mild but potentially visually significant changes in the outer retina reported after subretinal gene therapies underscore the need for a better understanding of the pathophysiology of the outer retinal abnormalities after subretinal delivery of gene therapies in NHPs and in patients.
As noted above, structural changes following the subretinal injection in NHPs treated with AAV2-hRPE65v2 appear to differ in important ways from the observations in patients. Could the differences be explained by differences in the surgical procedures and peri-operative medications used in human subretinal surgery versus the NHP studies reported in this work? Humans are expected to survive this intervention for decades, as opposed to just months in the NHP experiments. A vitrectomy is performed in patients as a step prior to the subretinal injections to reduce the risk of post-surgical vitreoretinal adhesions and tractions. A similar procedure in the smaller NHP eye would increase the risks of procedural complications confounding the interpretation of potential vector-related toxicity. Similarly, the surgical complexity of smaller eyes has limited the approval of voretigene neparvovec-rzyl for use in human infants. The less traumatic procedure in NHPs predicts less rather than more structural changes and would not explain the localized, both in extent (within the bleb), as well as in depth (at the POS and RPE), structural abnormalities observed post-injection. Human subretinal injections delivering AAV2-hRPE65v2 in phase I-III trials or after FDA approval of voretigene neparvovec-rzyl also include peri-operative treatment with prednisone, whereas no systemic steroids were used in the present NHP studies. In this work they were purposely omitted to avoid interference with the development of an immune response and inflammation after ipsilateral readministration of the vector. Thus, the results from this preclinical study in NHPs likely reflect what would be the "worst-case" scenario of ipsilateral readministration in humans. Studies controlling for these variables are needed to understand the differences between the human and NHP outcomes.
In summary, the results support the overall safety of the ipsilateral readministration of AAV2-hRPE65v2. Localized structural abnormalities confined to the outer retina and RPE after readministration of the treatment in NHPs do not differ from those observed after single or contralateral administration of this therapy. The structural changes observed after administration of AAV2-hRPE65v2 in NHPs contrast from the unchanged appearance of the human retina exposed to the same vectors, suggesting there may be local immunologic responses in NHPs retinas after the subretinal injections that escape detection with current assays, and/or differences between human and NHP outer retinas that influence the response to these treatments. Documentation of the immunologic profile, of the dynamics of subretinal fluid entry and reabsorption from the subretinal following single injections in NHPs, testing control vehicles without viral capsids, and the evaluation of outcomes with and without immunosuppression, as well as the use of more locally sensitive immunologic assays, are needed to narrow down the alternatives.
MATERIALS AND METHODS
Animals, Study Design, and Ocular Surgery
The studies were in compliance with local and federal guidelines and were carried out under an Institutional Review Board approved protocol (The Children's Hospital of Philadelphia, IACUC protocol 1061, and the University of Pennsylvania IRB protocol 815348) and were in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research (Association for Research in Vision and Ophthalmology, Rockville, MD). NHPs were selected for study due to similarities to humans in ocular anatomy, vision, and immune response.
The study was conceived as a prospective observational study. Included were three 7-to 9-year-old NHPs-two cynomolgus and one rhesus macaque primate. After a baseline evaluation (see below), each animal received subretinal injections of the study agent in each eye followed 2 months later by readministration of the same agent to each eye (Figure 1 ). The subretinal injection procedure was carried out using sterile instrumentation, surgical fields, and injectable and topical medications. The NHP eye is $70% the diameter of the mature human eye, approximately the size of that of an infant. 58 The smaller eye size increases the risk of complications due to vitrectomy and fluid-air exchange used in the human surgery, and in fact justifies the exclusion of infants from the FDA-approved use of Luxturna. 12 In this study, we felt that a better understanding of the toxicity could be gained by performing the less invasive, lower risk procedure. The subretinal injections were thus administered without a previous vitrectomy but the procedure was otherwise identical to that used in patients. 12, 24 The injections were performed under direct visualization through an operating microscope after an AC paracentesis (ACP) following procedures detailed elsewhere. 24 In brief, a needle was inserted through a trocar, introduced by sclerotomy, at the 2 or 10 o'clock position, which was then advanced through the vitreous to penetrate the retina in the posterior pole. Under microscopic control, 100-200 mL of the agent (resulting in doses of 1.0-2.0 E 11 vector genomes [vg]) was manually injected into the subretinal space, thereby raising a dome-shaped retinal detachment (bleb). This dose was similar (within one half a log unit) to the dose used in the phase III RPE65 clinical trials carried out at The Children's Hospital of Philadelphia and University of Iowa and as recommended for treatment with Luxturna, 1.5 E 11 vg. The solution was not drained, but was resorbed within a few h by the retina. The sclerotomy site was sutured with absorbable suture. After each procedure, a subconjunctival injection of 15 mg of Kenalog solution (40 mg/mL) was delivered and the ocular surface was dressed with PredG (prednisolone acetate-gentamicin, 0.3%/0.6%; Allergan) ointment. Other than that, no immunosuppression was administered. Ophthalmoscopic examinations were carried out prior to and immediately following subretinal injection, post-operative day 3 for each injection, and prior to euthanasia (Figure 1) . Venous blood was collected at baseline before the subretinal injections, at 2 week intervals following the readministration and at termination of the study. PBMCs and sera were isolated from the venous blood samples. The PBMCs were purified and stored in vapor phase liquid nitrogen, and sera were frozen at À80 C until testing. Aqueous humor samples to measure AAV-capsid-specific antibodies were obtained by ACPs at scheduled intervals (Figure 1 ). ACPs were performed in a sterile manner using a tuberculin syringe attached to a 30G hypodermic needle; a maximum of up to 100 mL of aqueous fluid was collected. At the termination of the study, animals were euthanized and samples collected for immune assays, immunohistochemistry, and histopathology ( Figure 1) .
Study Agent
AAV2-hRPE65v2 contains hRPE65 cDNA under control of a constitutive promoter (a hybrid chicken b-actin promoter with a cytomegalovirus enhancer) and a long stuffer sequence designed to prevent reverse packaging. 10 This is the same plasmid that was used to generate the reagent used in phase I, follow-on, and phase III clinical trials for RPE65 deficiency at The Children's Hospital of Philadelphia and the University of Iowa as well as the now commercially available vector (voretigene neparvovec-rzyl, Spark Therapeutics, PA, USA). 11, 12, 22, 23, 59 The rAAV used in this study was manufactured by the Research Vector Core at the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania Perelman School of Medicine-not Spark Therapeutics-and so is termed AAV2-hRPE65v2 to avoid confusion with the GMP-generated reagent. The virus was manufactured after triple transfection of HEK293 cells and was isolated and purified by microfluidization, filtration, cation exchange chromatography (POROS 50HS; HE Healthcare, Piscataway, NJ, USA), density gradient ultracentrifuga-tion, and diafiltration in PBS. This combination provides highly purified, transgene cassette-containing AAV particles and efficiently removes empty capsids and residual cesium chloride. The purified virus, along with 0.001% Pluronic F-68 (PF68; BASF, Ludwigshafen, Germany), was then passed through a 0.22-mm filter and stored frozen (-80 C) in sterile tubes until use. Quality control procedures included SDS-PAGE and silver staining (for vector purity), quantitative real-time PCR (to assess vg concentration), osmolality, pH, and endotoxin testing.
In vivo Retinal Imaging
Retinal imaging was performed in fully anesthetized animals. A heating pad maintained body temperature during the experiments. Vital signs were monitored periodically with a pulse oximeter and rectal thermometer. At the completion of procedures, animals were monitored closely through recovery. Pupils were dilated with topical tropicamide (1%) and phenylephrine (2%). Eyes were kept opened with an eye speculum inserted after topical anesthesia with proparacaine-HCL (1%). Corneal lubrication and clarity were ensured by frequent instillation of preservative-free artificial tears. Retinal imaging was performed 1.5 months after the first post-injection and 1 month after the readministration (Figure 1 ). En face retinal imaging was performed with NIR (790 nm) REF and FAF with NIR (820 nm) and SW (488 nm) excitation lights using a commercially available scanning laser ophthalmoscope camera integrated with a SD-OCT system (Spectralis, Heidelberg Engineering, Carlsbad, CA, USA). Overlapping en face imaging fields were collected with 30 and 55 lenses extending into the midperiphery to cover as much as possible the injected regions. Color fundus photography was performed with a wide-angle contact lens system (RetCam3 instrument, Natus Medical, Pleasanton, CA, USA). SD-OCT scanning was performed with 9 mmlong horizontal and vertical cross-sections through the fovea and overlapping 30 Â 25 mm raster scans extending into the near midperiphery. Histological retinal laminae were quantified with the builtin automatic segmentation of the Spectralis system, supervised to ensure correct identification of the different laminar boundaries by visual inspection and with the use of longitudinal reflectivity profiles (LRPs) extracted with available analysis software (ImageJ; https:// imagej.nih.gov/ij/; provided in the public domain by the NIH, Bethesda, MD, USA). 45 Total retinal thickness topography maps were generated, which in conjunction with en face imaging (NIR-REF and NIR-FAF) were used to visualize the treated regions as ROIs where a more focused analysis of the segmentation took place. Segmentation parameters examined within ROI included: 1, total retinal thickness, defined as the distance between the internal limiting membrane (ILM) and the basal side of the RPE signal at the level of the BM; 2, inner retinal thickness, defined as the distance between the ILM and the OPL; 3, ONL thickness, defined as the distance between the OPL and the ELM; 4, EZ band to the RPE/BM, defined as the distance between these two bands on SD-OCT. 37, 44 Smaller regions within the ROI that co-registered as judged by co-registration of vascular landmarks before and after treatment were similarly scaled and rotated and comparisons were made between pre-and post-injection parameters.
Necropsy, Histopathology, and Immunohistochemistry
At the conclusion of the studies, animals were euthanized, AC fluid and vitreous samples were collected, and eyes were enucleated. The globes were fixed 24 h in 4% paraformaldehyde in PBS before OCT embedding and cryosectioning. The posterior pole was isolated. Retina and underlying RPE/choroid were cryoprotected in 30% sucrose in PBS and frozen. Cryosections were made at 12 mm and designated sections were stained with DAPI or processed for immunohistochemistry for RPE65.
Immunohistochemistry was carried out using a rabbit anti-mouse RPE65 (Novus Biologicals, Centennial, CO, USA) and a horseradish peroxidase-conjugated anti-mouse secondary antibody (Amersham, Little Chalfont, United Kingdom) prior to DAB staining with kit (Abcam, Cambridge, MA, USA) or stained with H&E. Slides were evaluated in a masked fashion by a board-certified ocular pathologist (V. Lee).
ELISpot Assays
IFN-g assay on PBMCs were performed as previously described. 24 Response to an antigen was considered positive when the number of spot-forming units (SFUs) per 200,000 PBMCs was higher than 50 SFUs per 200,000 PBMCs and three or more times the SFU per 200,000 PBMCs measured for the medium negative control. Phorbol myristate acetate (PMA) was used at a final concentration of 5 ng/mL with ionomycin at 2 mM as a positive stimulant to ensure an equivalent number of functional T cells per well. For the experimental reagents, RPE65 peptide libraries were generated by Mimotopes (Minneapolis, MN, USA) and consisted of 105 overlapping 15-mers. Purified empty AAV2 capsids were used to test cell-mediated responses to the AAV capsid as previously described. 12 SEMs were calculated as the SD of the readings divided by the square root of the number of readings.
NAb Assay and ELISA Antibody to AAV2 NAb titer to AAV2 was determined as previously described with a b-galactosidase assay. 24 The positive control was maximal transduction of AAV2-LacZ without the addition of serum to the sample, while the negative control contained buffer only. Human sera samples previously assayed to be positive for antibodies to the AAV2 capsid were used as reagent controls. 24 ELISA for Antibodies to RPE65 Antibody titer to RPE65 was determined with an ELISA by modification of previously described methods. 10, 23, 24 The positive control was the PETLET rabbit anti-mouse RPE65 antibody (gift of Dr. Michael Redmond). The titer was defined as the reciprocal of the highest sample dilution such that the mean optical density for the test antigen was at least three times that for the control antigen and at least three times the background level, determined from the buffer-only negative control. BSA was used as a negative antigen control.
Treatment in Human
A single individual with RPE65-LCA was treated clinically with AAV2-hREP65v2 (voretigene neparvovec-rzyl, Luxturna, Spark Therapeutics, Philadelphia, PA, USA) and imaged with SD-OCT and FAF as previously described. 44 The treatment administration and imaging protocol used in the NHP experiments were delivered following the protocols used in patients using similar surgical technique and the same imaging instrumentation. 12, 44, 60 Informed consent was obtained both clinically and for the imaging portion of the study after explanation of the nature of the study. Procedures complied with the Declaration of Helsinki and were approved by the institutional review board of the University of Pennsylvania (IRB #815348).
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